Business Standard

Thursday, December 26, 2024 | 06:23 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

UK regulator approves Moderna's Covid shot for 12 to 17-year-olds

While most children develop mild or no symptoms with COVID-19, they are still able to spread the virus and some remain at risk of becoming seriously ill.

Moderna Covid-19 vaccine
Premium

Reuters
 The UK's health regulator has approved Moderna's COVID-19 vaccine for use in children aged 12 to 17 years, it said on Tuesday, weeks after Pfizer's shot was given the green light for deployment ahead of schools reopening.
 
The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed the vaccine, known as Spikevax, is safe and effective in this age group, it said.
 
While most children develop mild or no symptoms with COVID-19, they are still able to spread the virus and some remain at risk of becoming seriously ill.
 
Moderna's vaccine was recommended for use in adolescents by European regulators

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in